GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (TSXV:MIR) » Definitions » Capex-to-Revenue

MedMira (TSXV:MIR) Capex-to-Revenue : 0.00 (As of Jan. 2024)


View and export this data going back to 1999. Start your Free Trial

What is MedMira Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

MedMira's Capital Expenditure for the three months ended in Jan. 2024 was C$0.00 Mil. Its Revenue for the three months ended in Jan. 2024 was C$0.15 Mil.

Hence, MedMira's Capex-to-Revenue for the three months ended in Jan. 2024 was 0.00.


MedMira Capex-to-Revenue Historical Data

The historical data trend for MedMira's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Capex-to-Revenue Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.02 0.07 -

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MedMira's Capex-to-Revenue

For the Biotechnology subindustry, MedMira's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where MedMira's Capex-to-Revenue falls into.



MedMira Capex-to-Revenue Calculation

MedMira's Capex-to-Revenue for the fiscal year that ended in Jul. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.001) / 0.433
=0.00

MedMira's Capex-to-Revenue for the quarter that ended in Jan. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.149
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira  (TSXV:MIR) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


MedMira Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of MedMira's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (TSXV:MIR) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.